newsfilter
← Latest News
GlobeNewswire·

TRexBio Announces Closing of Initial Public Offering

  • TRex Bio, Inc. closed its initial public offering of 8,333,334 shares of common stock at $14.00 per share.
  • The offering generated approximately $116.7 million in aggregate gross proceeds before deducting underwriting discounts & commissions.
  • All shares in the offering were sold by TRexBio.
  • TRexBio's common stock began trading on the Nasdaq Global Select Market under the ticker symbol "TRXB".
  • J.P. Morgan, Evercore ISI, Cantor, & Stifel served as lead book-running managers, with Wedbush PacGrow acting as book-running manager.
  • The SEC registration statement (File No. 333-299018) became effective on October 8, 2026.
  • TRexBio is a clinical-stage biotechnology company focused on tissue Treg biology & immunoregulatory medicines for autoimmune & inflammatory diseases.
  • The company utilizes its Deep Biology Platform to map immune dysregulation drivers & develop therapeutic candidates across its pipeline.
  • TRexBio is headquartered in South San Francisco, California.